117 related articles for article (PubMed ID: 38339821)
41. Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas.
Lin LH; Allison DHR; Feng Y; Jour G; Park K; Zhou F; Moreira AL; Shen G; Feng X; Sabari J; Velcheti V; Snuderl M; Cotzia P
Mod Pathol; 2021 Dec; 34(12):2168-2174. PubMed ID: 34362997
[TBL] [Abstract][Full Text] [Related]
42. Factors affecting the success of next-generation sequencing in cytology specimens.
Roy-Chowdhuri S; Goswami RS; Chen H; Patel KP; Routbort MJ; Singh RR; Broaddus RR; Barkoh BA; Manekia J; Yao H; Medeiros LJ; Staerkel G; Luthra R; Stewart J
Cancer Cytopathol; 2015 Nov; 123(11):659-68. PubMed ID: 26230354
[TBL] [Abstract][Full Text] [Related]
43. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
[TBL] [Abstract][Full Text] [Related]
44. Utilization of Dynamic Telecytopathology for Rapid Onsite Evaluation of Touch Imprint Cytology of Needle Core Biopsy: Diagnostic Accuracy and Pitfalls.
Perez D; Stemmer MN; Khurana KK
Telemed J E Health; 2021 May; 27(5):525-531. PubMed ID: 32833582
[No Abstract] [Full Text] [Related]
45. Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.
Zazo S; Pérez-Buira S; Carvajal N; Plaza-Sánchez J; Manso R; Pérez-González N; Dominguez C; Prieto-Potin I; Rubio J; Dómine M; Lozano V; Mohedano P; Carcedo D; Carias R; Rojo F
Cancer Med; 2024 Feb; 13(3):e6827. PubMed ID: 38213074
[TBL] [Abstract][Full Text] [Related]
46. The Performance of an Extended Next Generation Sequencing Panel Using Endobronchial Ultrasound-Guided Fine Needle Aspiration Samples in Non-Squamous Non-Small Cell Lung Cancer: A Pragmatic Study.
Zhang C; Kim RY; McGrath CM; Andronov M; Haas AR; Ma KC; Lanfranco AR; Hutchinson CT; Morrissette JJD; DiBardino DM
Clin Lung Cancer; 2023 Mar; 24(2):e105-e112. PubMed ID: 36599742
[TBL] [Abstract][Full Text] [Related]
47. Fine-Needle Aspiration, Touch Imprint, and Crush Preparation Cytology for Diagnosing Thyroid Malignancies in Thyroid Nodules.
Ahmadinejad M; Aliepour A; Anbari K; Kaviani M; Ganjizadeh H; Nadri S; Foroutani N; Meysami M; Almasi V
Indian J Surg; 2015 Dec; 77(Suppl 2):480-3. PubMed ID: 26730049
[TBL] [Abstract][Full Text] [Related]
48. Suitability of transbronchial brushing cytology specimens for next-generation sequencing in peripheral lung cancer.
Furuya N; Matsumoto S; Kakinuma K; Morikawa K; Inoue T; Saji H; Goto K; Mineshita M
Cancer Sci; 2021 Jan; 112(1):380-387. PubMed ID: 33124129
[TBL] [Abstract][Full Text] [Related]
49. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
[TBL] [Abstract][Full Text] [Related]
50. Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing.
Kage H; Kohsaka S; Shinozaki-Ushiku A; Hiraishi Y; Sato J; Nagayama K; Ushiku T; Takai D; Nakajima J; Miyagawa K; Aburatani H; Mano H; Nagase T
Cancer Sci; 2019 Aug; 110(8):2652-2657. PubMed ID: 31222846
[TBL] [Abstract][Full Text] [Related]
51. Touch imprint smear: A prerequisite to obtain better quality and "true" tumor RNA in breast tissues.
Yadav R; Kumari L; Goel S; Kaur D; Dahiya D; Kumar Y; Dey P; Bhatia A
Pathol Res Pract; 2023 Jul; 247():154581. PubMed ID: 37267722
[TBL] [Abstract][Full Text] [Related]
52. Performance of a 50-gene next generation sequencing panel with post-centrifuge supernatant cytology fluid in non-small-cell lung cancer.
Tafoya M; Judd A; Chiotti K; Dearen K; Jiron K; Chabot-Richards D; Broehm CJ
Diagn Cytopathol; 2021 Nov; 49(11):1173-1178. PubMed ID: 34339108
[TBL] [Abstract][Full Text] [Related]
53. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
54. Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
Bonanno L; Pavan A; Ferro A; Calvetti L; Frega S; Pasello G; Aprile G; Guarneri V; Conte P;
Oncologist; 2020 Dec; 25(12):e1996-e2005. PubMed ID: 32557976
[TBL] [Abstract][Full Text] [Related]
55. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
56. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
57. Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
Reynolds JP; Zhou Y; Jakubowski MA; Wang Z; Brainard JA; Klein RD; Farver CF; Almeida FA; Cheng YW
Cancer Cytopathol; 2017 Mar; 125(3):178-187. PubMed ID: 28085233
[TBL] [Abstract][Full Text] [Related]
58. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
[TBL] [Abstract][Full Text] [Related]
59. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
[TBL] [Abstract][Full Text] [Related]
60. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM
Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
